Comparative Pharmacology
Head-to-head clinical analysis: GYNE SULF versus SULFANILAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE SULF versus SULFANILAMIDE.
GYNE-SULF vs SULFANILAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GYNE-SULF (sulfisoxazole) is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for the active site of dihydropteroate synthase, thereby blocking folate synthesis and bacterial growth.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folic acid synthesis.
Intravaginal: One full applicator (approximately 5 g of 2% cream, containing 100 mg sulfanilamide) inserted intravaginally once daily (at bedtime) for 7-10 days. Alternatively, one vaginal suppository (containing 250 mg sulfanilamide) inserted intravaginally twice daily (morning and bedtime) for 7-10 days.
2-4 g orally initially, then 2-4 g every 4-6 hours, not to exceed 12 g/day; intravenous: 4-8 g/day in divided doses every 6-8 hours.
None Documented
None Documented
Clinical Note
moderateSulfanilamide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide."
Clinical Note
moderateSulfanilamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin."
Clinical Note
moderateSulfanilamide + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine."
Clinical Note
moderateTerminal elimination half-life: 10-12 hours (normal renal function). In renal impairment (CrCl <30 mL/min): up to 24-48 hours.
Terminal elimination half-life: 7-12 hours; prolonged in renal impairment (up to 24-48 hours).
Renal: 80% (unchanged). Biliary/fecal: 15% as metabolites. Metabolized by reduction and acetylation; parent and metabolites undergo glomerular filtration and active tubular secretion.
Primarily renal via glomerular filtration and tubular secretion; ~50-70% excreted unchanged in urine; biliary/fecal excretion minimal (<5%).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
Sulfanilamide + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfanilamide."